Remarkably, a large number of U2AF1 mutational landscapes in various hematologic tumors have been reported, including MDS, MDS/MPN, MPN, AML, and chronic myeloid leukemia (CML). This evidence concerns the gene U2AF1 and myeloproliferative disorder.